CASSANDRA: Neoadjuvant PAXG Versus mFOLFIRINOX for Resectable, Borderline Resectable PDAC

10 Views
Published
Michele Reni, MD, Oncology Scientific Institute San Raffaele, breaks down the CASSANDRA study, a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III pancreatic ductal adenocarcinoma.

Dr. Reni comments on the 3-year event-free survival doubling from 14% with mFOLFIRINOX to 30% with PAXG, how practice-changing this may be, and more.
Category
Oncology
Be the first to comment